Lucknow: India’s Council Of Scientific and Industrial Research, is putting its prestige behind a anti-diabetes Ayurvedic preparation, named BGR-34. The natural drug is a combination of plant extracts. The drug is expected to improve the management of type-II diabetes mellitus.
The drug has been jointly developed by two CSIR laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plant (CIMAP). It was launched on the 62nd annual day of the NBRI for commercial manufacturing and marketing by M/s Aimil Pharamaceuticals Pvt Ltd, New Delhi.
This is the first such drug that has origins in Ayurveda that has been tested under modern parameters. Though there are other ayurveda drugs available in the market currently, BGR-34 is the first one to have gone through rigorous clinical trials.
The drug will help maintain normal blood glucose levels, reduce chances of complications due to persistent high blood glucose levels and impart a good quality life to patients with high blood sugar levels.
First launched by India’s Vice-President Hamid Ansari in February last year at Vigyan Bhawan, New Delhi, the product will soon be commercially available in India.
“We will manufacture it now and it will be available in market shortly, may be in the next 15 days,” V S Kapoor, marketing head of Aimil Pharmaceuticals for UP and Delhi told the media.